Definium Therapeutics Inc. saw its stock jump roughly 60% on Monday after the company released data from a late‑stage trial of its experimental psychedelic therapy for major depressive disorder. The surge marked the sharpest intraday move for the biotech in months, drawing attention from both investors and clinicians.

The trial results were described as “groundbreaking,” suggesting the drug produced statistically significant improvements over placebo in key depression rating scales. Such outcomes could position Definium as a front‑runner in the burgeoning psychedelic‑medicine market, where few candidates have advanced to Phase III and secured regulatory endorsement.

Investors have been watching Definium’s cash burn and partnership pipeline closely. The company recently secured a $200 million private placement to fund the trial and expand manufacturing capacity. Success in the trial may unlock additional capital, enable licensing talks with larger pharma firms, and boost valuation multiples.

While the data energize a sector still grappling with stigma, analysts caution that broader adoption hinges on FDA review and post‑marketing safety monitoring. Nonetheless, the immediate market reaction underscores how a single positive readout can reshape a small biotech’s trajectory, delivering tangible wealth to shareholders overnight.